Benzinga's Top Pre-Market NASDAQ Gainers (EXEL, DNDN, DRYS, ARUN)

Exelixis Inc EXEL rose 20.13% to $5.67 in the pre-market session. EXEL has reported interim data from the patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184. Dendreon Corporation DNDN added 9.14% to $39.15 in the pre-market session. A US advisory panel supported DNDN's prostate-cancer treatment Provenge. DryShips Inc DRYS moved up 8.67% to $5.64 in the pre-market session. DRYS reported upbeat Q3 results. Aruba Networks Inc ARUN soared 7.65% to $22.95 in the pre-market trading. ARUN swung to Q1 profit. Read more from Benzinga's Markets.